Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/ofid/ofaa286 http://scihub22266oqcxt.onion/10.1093/ofid/ofaa286 32929402!7454824!32929402     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32929402&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Open+Forum+Infect+Dis 2020 ; 7 (9): ofaa286 Nephropedia Template TP {{tp|p=32929402|t=2020. The Course of Mild and Moderate COVID-19 Infections-The Unexpected Long-Lasting Challenge |pdf=|usr=}}{{32929402}} gab.com Text The Course of Mild and Moderate COVID-19 Infections-The Unexpected Long-Lasting Challenge JO: Open Forum Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32929402 #FOAvip BACKGROUND: The course of disease in mild and moderate COVID-19 has many implications for mobile patients, such as the risk of spread of the infection, precautions taken, and investigations targeted at preventing transmission. METHODS: Three hundred thirty-one adults were hospitalized from January 21 to February 22, 2020, and classified as severe (10%) or critical (4.8%) cases; 1.5% died. Two hundred eighty-two (85.2%) mild or moderate cases were admitted to regular wards. Epidemiological, demographic, clinical, chest computed tomography (CT) scan, laboratory, treatment, and outcome data from patient records were analyzed retrospectively. RESULTS: Patients were symptomatic for 9.82+/-5.75 (1-37) days. Pulmonary involvement was demonstrated on a chest CT scan in 97.9% of cases. It took 16.81+/-8.54 (3-49) days from the appearance of the first symptom until 274 patients tested virus-negative in naso- and oropharyngeal (NP) swabs, blood, urine, and stool, and 234 (83%) patients were asymptomatic for 9.09+/-7.82 (1-44) days. Subsequently, 131 patients were discharged. One hundred sixty-nine remained in the hospital; these patients tested virus-free and were clinically asymptomatic because of widespread persisting or increasing pulmonary infiltrates. Hospitalization took 16.24+/-7.57 (2-47) days; the time interval from the first symptom to discharge was 21.37+/-7.85 (3-52) days. CONCLUSIONS: With an asymptomatic phase, disease courses are unexpectedly long until the stage of virus negativity. NP swabs are not reliable in the later stages of COVID-19. Pneumonia outlasts virus-positive tests if sputum is not acquired. Imminent pulmonary fibrosis in high-risk groups demands follow-up examinations. Investigation of promising antiviral agents should heed the specific needs of mild and moderate COVID-19 patients. Twit Text FOAVip The Course of Mild and Moderate COVID-19 Infections-The Unexpected Long-Lasting Challenge ????Open Forum Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32929402 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32929402 #FOAvip English Wikipedia <ref>{{Cite pmid|32929402}}</ref> The Course of Mild and Moderate COVID-19 Infections-The Unexpected Long-Lasting Challenge #MMPMID32929402 Xia L; Chen J; Friedemann T; Yang Z; Ling Y; Liu X; Lu S; Li T; Song Z; Huang W; Lu Y; Schroder S; Lu H Open Forum Infect Dis 2020[Sep]; 7 (9): ofaa286 PMID32929402show ga BACKGROUND: The course of disease in mild and moderate COVID-19 has many implications for mobile patients, such as the risk of spread of the infection, precautions taken, and investigations targeted at preventing transmission. METHODS: Three hundred thirty-one adults were hospitalized from January 21 to February 22, 2020, and classified as severe (10%) or critical (4.8%) cases; 1.5% died. Two hundred eighty-two (85.2%) mild or moderate cases were admitted to regular wards. Epidemiological, demographic, clinical, chest computed tomography (CT) scan, laboratory, treatment, and outcome data from patient records were analyzed retrospectively. RESULTS: Patients were symptomatic for 9.82+/-5.75 (1-37) days. Pulmonary involvement was demonstrated on a chest CT scan in 97.9% of cases. It took 16.81+/-8.54 (3-49) days from the appearance of the first symptom until 274 patients tested virus-negative in naso- and oropharyngeal (NP) swabs, blood, urine, and stool, and 234 (83%) patients were asymptomatic for 9.09+/-7.82 (1-44) days. Subsequently, 131 patients were discharged. One hundred sixty-nine remained in the hospital; these patients tested virus-free and were clinically asymptomatic because of widespread persisting or increasing pulmonary infiltrates. Hospitalization took 16.24+/-7.57 (2-47) days; the time interval from the first symptom to discharge was 21.37+/-7.85 (3-52) days. CONCLUSIONS: With an asymptomatic phase, disease courses are unexpectedly long until the stage of virus negativity. NP swabs are not reliable in the later stages of COVID-19. Pneumonia outlasts virus-positive tests if sputum is not acquired. Imminent pulmonary fibrosis in high-risk groups demands follow-up examinations. Investigation of promising antiviral agents should heed the specific needs of mild and moderate COVID-19 patients. ?The Course of Mild and Moderate COVID-19 Infections-The Unexpected Lon(epmc).pdf DeepDyve Pubget Overpricing